Oligomerix names new interim CEO to push Alzheimer's drug

Oligomerix just appointed Dr. Cara Cassino as interim CEO, tapping her 25 years of drug development experience to advance its Alzheimer's pipeline. Cassino has over 25 FDA and EMA drug approvals under her belt from previous roles at major pharma companies like Boehringer Ingelheim, signaling a push for speed to market in the neurodegenerative space.